Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

By / 23/10/2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.